Bipolar disorder is a severe and heterogeneous mental disorder. Despite great advances in neuroscience over the past decades, the precise causative mechanisms at the transmitter, cellular or network level have so far not been unraveled. As a result, individual treatment decisions cannot be tailor-made, and the uncertain prognosis is based on clinical characteristics alone. Although a subpopulation of patients has an excellent response to pharmacological monotherapy, other subpopulations have been less well served by the medical system and therefore require more focused attention (e.g. patients at early stages of bipolar disorder, patients with an unstable highly relapsing course, patients with acute suicidal ideation). To address these areas of unmet needs, a research consortium of ten universities across Germany has therefore implemented a 4-year research agenda including three randomized controlled trials, one epidemiological trial and one cross-sectional trial (BipoLife). The topics under investigation will be the improvement of early recognition, specific psychotherapy, and smartphones as an aid for early episode detection and biomarkers of lithium response. A subset of patients will be investigated utilizing biomaterials, neuroimaging (fMRI), and neurophysiology (EEG).